Intensifying treatment in type 2 diabetes with chronic kidney disease
Mr O'Sullivan is 58 and has had type 2 diabetes for nine years. His BMI is 34 kg/m². Current medication: metformin 1 g twice daily, ramipril 10 mg daily, atorvastatin 20 mg daily. HbA1c is 80 mmol/mol. eGFR is 40 mL/min/1.73 m², and urine albumin-to-creatinine ratio is 18 mg/mmol on a repeat sample. Blood pressure 144/88 mmHg. He reports fatigue and nocturia but no hypoglycaemia. He has heard about tablets that protect the kidneys and is keen to avoid insulin. Examination: foot pulses present, monofilament sensation intact, no ulcers; fundoscopy last year normal. He does not smoke. He asks what else can be done.
1. Interpret his results against treatment targets and identify the priorities.
Read the worked answer
His HbA1c of 80 mmol/mol is well above the usual target of 58 mmol/mol (and above a less stringent 64 mmol/mol for some frail patients). eGFR 40 is CKD G3b and ACR 18 mg/mmol is A2, giving G3bA2-high risk of progression. Blood pressure 144/88 is above the target of <140/90, and ideally <130/80 with albuminuria if tolerated. BMI 34 contributes to both glycaemia and blood pressure.
The priorities are renal and cardiovascular protection, not simply lowering HbA1c. Fatigue and nocturia could reflect hyperglycaemia, anaemia of CKD, vitamin B12 deficiency from long-term metformin, sleep apnoea, or depression. Check full blood count, ferritin, B12, thyroid function, liver function, and repeat the ACR. Review foot and eye screening, vaccinations, and whether he has been offered structured education. No hypoglycaemia risk currently because metformin alone does not cause it.
2. What medication changes would you make, with doses and monitoring? Explain the renal criteria.
Read the worked answer
Continue metformin at 1 g twice daily. With eGFR 30–45 the maximum dose is 2 g/day and renal function should be checked every three to six months; stop if eGFR falls below 30 or during acute illness with dehydration. Add empagliflozin 10 mg daily: initiation is permitted at eGFR ≥20, and it slows CKD progression, reduces heart failure and cardiovascular events, and lowers HbA1c, weight and blood pressure modestly. Counsel about genital thrush, volume depletion, euglycaemic ketoacidosis, and sick-day rules-stop if vomiting, unable to eat, or before surgery.
Increase atorvastatin to 40 mg as high-intensity statin therapy for combined diabetes and CKD. For blood pressure, reassess after four weeks; if still >140/90, add amlodipine or indapamide, since ramipril is already at 10 mg. If HbA1c remains above target after three to six months, a GLP-1 receptor agonist such as semaglutide would address weight and cardiovascular risk; insulin is not needed now. Check urea and electrolytes two to four weeks after starting the SGLT2 inhibitor.
3. How would you address his reluctance about insulin and structure follow-up?
Read the worked answer
Explore what he has heard and why insulin worries him-fear of injections, weight gain, hypoglycaemia, or work implications. Explain that insulin is not currently required and that empagliflozin is a once-daily tablet; a GLP-1 injection would only be considered later if targets are not met. Use teach-back to confirm understanding and agree explicit goals, including weight and blood pressure as well as HbA1c.
Follow up at four weeks for blood pressure, tolerance and adherence; repeat HbA1c at three months. Check renal function and ACR at least annually, more often if medication changes. Reinforce sick-day rules: stop empagliflozin and metformin if acutely unwell, vomiting or fasting, and seek advice. Refer for weight management and consider sleep apnoea assessment given nocturia and BMI 34. Ensure retinal screening, foot review, influenza and pneumococcal vaccination, and dental care are up to date. Document the plan and give written information.